NewAmsterdam Pharma Co N.V. (NAMS) · Aug 5, 2026 · Company update

Revenue beat is overshadowed by a wider loss and unchanged catalysts.

Revenue beat is overshadowed by a wider loss and unchanged catalysts.

The financial result was weaker than the headline revenue beat suggests. Published expectations clustered around roughly $2 million of quarterly revenue and a loss of about $0.43-$0.50 per share. Revenue reached $3.7 million, but it is supply revenue from Menarini and small relative to the development spend; the $64.1 million net loss implies roughly a $0.55 per-share loss based on period-end shares, worse than that EPS range. The year-ago revenue comparison is also flattered by a one-time $16.1 million Menarini development contribution, not a recurring commercial base. (Condensed Consolidated Statements of Operations and Comprehensive Loss; Second Quarter Financial Results)

MetricQ2 2026Q2 2025 / comparisonRead-through
Revenue$3.7M$19.1M; published consensus roughly $2MAbove consensus, but prior-year revenue included a $16.1M license-related contribution. (Statements of Operations; Second Quarter Financial Results)
Net loss$(64.1)M$(17.4)MLoss widened sharply; implied per-share loss was about $(0.55), versus published consensus of roughly $(0.43)-$(0.50). (Statements of Operations)
R&D expense$41.7M$27.5MHigher trial and personnel spending drove the weaker earnings result. (Statements of Operations; Second Quarter Financial Results)
Cash, equivalents and marketable securities$678.3M$728.9M at Dec. 31, 2025Still substantial, but down $50.6M year to date. (Balance Sheet; Cash Position)
Six-month operating cash use$(69.8)M$(74.1)MUnderlying operating cash use improved modestly year over year, partly tempering the larger accounting loss. (Cash Flow Statement)

The clinical and regulatory items largely confirm an already-known timeline rather than add a new catalyst. The favorable European CHMP opinion was announced in July, while the company again targets a European Commission decision later in 2026. Likewise, the PREVAIL interim analysis remains planned for Q4 2026, with results expected in Q1 2027; RUBENS topline data remain due by year-end 2026. Those are important value drivers, but this filing did not bring them forward or disclose new outcome data. (Clinical Development Updates; Upcoming Milestones and Ongoing Trials)

Cash remains a cushion, not a disclosed runway. The $678.3 million balance supports continued late-stage work and the planned Alzheimer’s study, but the company did not provide a cash-runway date. With R&D up 51% year over year and PREVAIL still the central unreported outcomes study, the financial picture remains one of funded execution rather than a de-risked earnings story. (Cash Position; Second Quarter Financial Results; Cash Flow Statement)

Net: the revenue beat is too small and non-recurring in character to offset the earnings shortfall, while the filing leaves the major 2026-27 milestones unchanged.

Original filing on SEC EDGAR

More NewAmsterdam Pharma Co N.V. news

Revenue beat is overshadowed by a wider loss and unchanged catalysts. | NAMS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.